Area of research
Radiology, Nuclear Medicine and Imaging · Oncology
Research interest
Research interests include Radiopharmaceutical Chemistry and Applications, Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research, and Glycosylation and Glycoproteins Research.
The Use of Glycine-Containing Peptide-Based Chelators for Labeling with <sup>99m</sup>Tc Improves the Imaging Properties of EpCAM-Targeting Designed Ankyrin Repeat Ec1.
Efficient <sup>68</sup>Ga Labeling of a B7-H3-Targeting Affibody Molecule via Acyclic Tris(hydroxypyridinone) Chelator: Effects on Biodistribution in a Preclinical Model.
Preclinical Evaluation of a <sup>177</sup>Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus.
Single-Photon Emission Computer Tomography Imaging of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Cancer Patients Using a Novel Peptide-Based Probe [<sup>99m</sup>Tc]Tc-BQ0413 with Picomolar Affinity to PSMA: A Phase I/II Clinical Study.
Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture.
The Impact of the Injected Mass of the Gastrin-Releasing Peptide Receptor Antagonist on Uptake in Breast Cancer: Lessons from a Phase I Trial of [<sup>99m</sup>Tc]Tc-DB8.
Synthesis and preclinical evaluation of gastrin releasing peptide receptor antagonist [<sup>18</sup>F]MeTz-PEG<sub>2</sub>-RM26 for positron emission tomography.
Affibody-Derived Drug Conjugates Targeting The Epidermal Growth Factor Receptor Are Potent And Specific Cytotoxic Agents.
Impact of Radiometal Chelates on In Vivo Visualization of Immune Checkpoint Protein Using Radiolabeled Affibody Molecules.
A preclinical study on the influence of linkers in [<sup>68</sup>Ga]Ga-NOTA-X-RM26 radiotracers for PET imaging of GRPR expression.
Reduction of Negative Charge in Mercaptoacetyl-Based Chelators Influences the Biodistribution of Prostate-Specific Membrane Antigen-Targeting Pseudopeptides Labeled with Technetium-99m.
Preclinical Positron Emission Tomography Imaging of B7-H3 Expression Using Affibody Molecules Labeled with Gallium-68.
Phase I Clinical Study with the GRPR-Antagonist [<sup>99m</sup>Tc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?
A New PSMA-targeted Radiopharmaceutical for Single-Photon Emission Computed Tomography
Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
Phase I Clinical Evaluation of Designed Ankyrin Repeat Protein [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-Ec1 for Visualization of EpCAM-Expressing Lung Cancer.
GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics.
Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with <sup>177</sup>Lu.
Evaluation of ABD-Linked RM26 Conjugates for GRPR-Targeted Drug Delivery.
Shorter Peptide Nucleic Acid Probes Improve Affibody-Mediated Peptide Nucleic Acid-Based Pretargeting.
Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology.
Two Novel [<sup>68</sup>Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar<sup>11</sup>]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer.
Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins <i>G3</i> for the <sup>99m</sup>Tc-Based Imaging of HER2-Expressing Malignant Tumors.
Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m.
Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts.
Phase I Trial of [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors.
Radionuclide Therapy of HER2-Expressing Xenografts Using [<sup>177</sup>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab.
Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [<sup>68</sup>Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation.
Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics.
Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.